Building on the work of University of Sydney researchers, Kira Biotech has raised $13.6m from investors including IP Group to progress antibodies for autoimmune diseases.
Kira Biotech, an Australia-based autoimmune disease therapy developer leveraging University of Sydney research, has obtained A$20m ($13.6m) in a series A round backed by commercialisation firm IP Group.
The round was led by venture capital firm OneVentures and was also backed by state government-owned innovation agency Advance Queensland’s Business Development Fund.
Founded in 2019, Kira Biotech is working on antibodies for autoimmune diseases which aim to renew the patient’s immune system tolerance – the mechanism whereby immune responses…
